Correlation Between Egetis Therapeutics and Combigene

Can any of the company-specific risk be diversified away by investing in both Egetis Therapeutics and Combigene at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Egetis Therapeutics and Combigene into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Egetis Therapeutics AB and Combigene AB, you can compare the effects of market volatilities on Egetis Therapeutics and Combigene and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Egetis Therapeutics with a short position of Combigene. Check out your portfolio center. Please also check ongoing floating volatility patterns of Egetis Therapeutics and Combigene.

Diversification Opportunities for Egetis Therapeutics and Combigene

-0.47

Correlation Coefficient

Egetis Therapeutics  Combigene

Very good diversification

The 3 months correlation between Egetis and Combigene is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding Egetis Therapeutics AB and Combigene AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Combigene AB and Egetis Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Egetis Therapeutics AB are associated (or correlated) with Combigene. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Combigene AB has no effect on the direction of Egetis Therapeutics i.e., Egetis Therapeutics and Combigene go up and down completely randomly.

Pair Corralation between Egetis Therapeutics and Combigene

Assuming the 90 days trading horizon Egetis Therapeutics AB is expected to generate 1.51 times more return on investment than Combigene. However, Egetis Therapeutics is 1.51 times more volatile than Combigene AB. It trades about 0.15 of its potential returns per unit of risk. Combigene AB is currently generating about 0.01 per unit of risk. If you would invest  394.00  in Egetis Therapeutics AB on April 23, 2025 and sell it today you would earn a total of  149.00  from holding Egetis Therapeutics AB or generate 37.82% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Egetis Therapeutics AB  vs.  Combigene AB

Egetis Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Egetis Therapeutics AB are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Egetis Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Combigene AB

Risk-Adjusted Performance

Very Weak

Over the last 90 days Combigene AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Combigene is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Egetis Therapeutics and Combigene

The main advantage of trading using opposite Egetis Therapeutics and Combigene positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Egetis Therapeutics position performs unexpectedly, Combigene can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Combigene will offset losses from the drop in Combigene's long position.

The idea behind Egetis Therapeutics AB and Combigene AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.